BeiGene is happy to be present at the 25th World Congress on Gastrointestinal Cancer
Cancer patients worldwide are challenged by unmet medical needs every day. BeiGene’s approach to cancer biology unites cutting-edge research models and processes for drug development with the scale of a global organization. We are advancing an innovative solid tumor portfolio, with the aim of discovering additional first-in-class or best-in-class medicines. We aim to ensure the accessibility and affordability of our medicines for far more patients around the world. Check this brochure to learn more about our company.
We would like to share with you how we are working to improve the lives of patients affected by cancers of the gastrointestinal tract.
Are you interested in our most recent publications in the field of gastrointestinal cancers?
RATIONALE-305 is a Phase 3 trial evaluating the efficacy and safety of tislelizumab, an anti-PD1 antibody, combined with chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic GC/GEJC. Results from the interim analysis presented at ASCO GI demonstrated a statistically significant and clinically meaningful improvement in overall survival versus placebo plus chemotherapy in patients with high PD-L1 expression (Moehler M, et al. Oral presentation at ASCO GI 2023). Stay tuned for the final results, which will be presented at the ESMO congress later this year.
RATIONALE-301 is a Phase 3 study evaluating tislelizumab vs sorafenib, a kinase inhibitor, as first-line systemic treatment for patients with unresectable HCC. According to results presented recently at ASCO, the anti-PD1 antibody demonstrated overall survival noninferiority, more durable antitumor response and a favorable safety profile in a European/North American subgroup (Vogel A, et al. Abstract 4082 presented at ASCO 2023). Results from the ≥65 years subgroup will be presented here, at the WCGIC.
Visit beigenemedical.info to find other relevant publications.
Other educational resources
Take a look at our pipeline to learn more about the high-quality, innovative medicines we are developing.
Tislelizumab mechanism of action
Among our investigational compounds, the anti-PD1 antibody tislelizumab is currently being studied in several global Phase 3 trials. Watch the MoA video to learn more about the mechanism of action.
To find more resources, please visit OncologyPRO, an educational portal for oncologists supported by unrestricted grants from different companies, including BeiGene.